The U.S. oral solid dosage contract manufacturing market size was estimated at USD 10.85 billion in 2022 and is expected to hit around USD 19.8 billion by 2032, poised to reach at a notable CAGR of 6.2% during the forecast period 2023 to 2032.
U.S. Oral Solid Dosage Contract Manufacturing Market Report Scope
|Market Size in 2023||USD 11.52 Billion|
|Market Size by 2032||USD 19.8 Billion|
|Growth Rate From 2023 to 2032||CAGR of 6.2%|
|Forecast Period||2023 to 2032|
|Segments Covered||Product type, Mechanism, End-user|
|Market Analysis (Terms Used)||Value (US$ Million/Billion) or (Volume/Units)|
|Report Coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Key Companies Profiled||Catalent, Inc.; Lonza; AbbVie Inc.; Aenova Group; Adare Pharma Solutions; Boehringer Ingelheim International GmbH; Jubilant Pharmova Limited; Patheon Pharma Services; Recipharm AB; Corden Pharma International; Siegfried Holding AG|
Advancements in drug delivery technology and increasing investments by Contract Development and Manufacturing Organizations (CDMOs) to enhance Oral Solid Dosage (OSD) development are major factors driving market growth. Technological advancements pertaining to the development and bulk manufacturing of OSD forms are the primary factors fast-tracking the commercialization of these products. Currently, a diverse array of dosage forms is accessible in the market. Nutraceutical and pharmaceutical industries consistently strive to develop OSD forms due to their ease of handling and consumption, and favorable adherence among patients.
Oral Solid Dosage (OSD) medications have exhibited substantial potential in alleviating COVID-19 symptoms. Pharmaceutical companies expedited the research, development, and distribution of pharmaceuticals to overcome the disease and address its signs. While significant attention globally was directed toward vaccine prospects, an alternative avenue displayed encouraging results, such as small-molecule OSD treatments such as hydroxychloroquine and azithromycin. Originally designed for less prevalent conditions such as malaria, these OSD medications gained immense traction as their efficacy against COVID-19 symptoms gained recognition.
Moreover, increasing demand for outsourcing OSD manufacturing among pharmaceutical companies has compelled contract manufacturers to expand their manufacturing facilities to support this growing demand. These expansions are made across the globe to increase their penetration in the OSD industry. Furthermore, the rising demand for generic drugs is also a key factor, given that many generics are OSD products. For instance, in April 2020, CoreRx, Inc., a CDMO, opened a new product development center in Clearwater, Florida to manufacture oral and topical dosage formulations.
Product Type Insights
Based on product type, the tablets segment accounted for the largest market share of 32.23% in 2022. Solid dosage products, particularly tablets, are considered economical, which is anticipated to promote segment growth. Furthermore, the tablet segment continues to embrace new technologies, such as continuous manufacturing and 3D printing, for further improvement in the efficiency of manufacturing processes, aiding segment growth. For instance, in May 2023, an Ohio-based contract manufacturer, The Technology House (TTH), acquired an SLA 750 3D printer from 3D Systems to improve and streamline its manufacturing processes.
The capsules segment is anticipated to register lucrative growth during the forecast period. The adoption of capsules in Oral Solid Dosage (OSD) forms due to various advantages, such as ease of swallowing, faster disintegration, and convenient absorption, is expected to drive market growth. Capsules can disintegrate more quickly, resulting in a more rapid medication release and absorption. This is advantageous for medicines that need to start working quickly.
The controlled release segment dominated the market and accounted for the largest revenue share of 51.91% in 2022. Recent advancements within the domain of oral controlled-release delivery systems, including dome tablets, dual drug tablets, intestinal patches, polymer nanosystems, and bioinspired delivery methods like exosomes have revolutionized the field, as Controlled-Release (CR) drug delivery systems maintain their pivotal role in disease treatment.
The immediate release segment is expected to advance at a substantial CAGR during the forecast period. The adoption of IR oral solid dosage forms has increased due to various factors that make them favorable for pharmaceutical developers and patients. IR formulations are made to rapidly release the active pharmaceutical ingredients (APIs) after consumption, immediately initiating the therapeutic effects. This is especially advantageous for drugs that need to provide instant relief or rapid symptom relief. Thus, the increasing adoption of IR dosage forms is expected to drive segment growth.
The large-size companies segment dominated the U.S. oral solid dosage contract manufacturing market with the highest revenue share of 54.97% in 2022. Large companies mostly prefer to avoid getting engaged in manufacturing difficulties and instead concentrate on their core skills, such as research, development, marketing, and distribution. Contract manufacturing allows them to concentrate on what they do best while leaving the manufacturing aspect to experts.
On the other hand, the medium and small size companies segment is expected to progress at a substantial CAGR during the forecast period. Research and development are frequently prioritized heavily by small- and medium-sized companies in order to introduce novel products to the market. Contract manufacturing allows them to delegate the manufacturing process, freeing up resources and time for R&D efforts.
Key Companies & Market Share Insights
Key companies undertake several strategic initiatives such as partnerships, expansions, new service launches, mergers, and acquisitions to maintain their position in the market. For instance, in January 2023, Aenova Group expanded its capsule filling capacity at the company’s Regensburg site by installing the state-of-the-art IMA Adapta 200 machine. In another instance, in May 2022, Catalent, Inc. announced an investment of USD 175 million to expand its flagship manufacturing facility for large-scale oral dose forms in Winchester, Kentucky. Some of the prominent players in the U.S. oral solid dosage contract manufacturing market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S. Oral Solid Dosage Contract Manufacturing market.
By Product Type